Literature DB >> 11864662

Serum CA-125 in preoperative patients at high risk for endometriosis.

Ya-Min Cheng1, Shan-Tair Wang, Cheng-Yang Chou.   

Abstract

OBJECTIVE: To investigate the factors contributing to the elevated level of CA-125 in endometriosis and to study whether CA-125 assay is useful to identify women who require preoperative bowel preparation.
METHODS: A total of 685 women undergoing surgery for endometriosis between July 1988 and June 1999 were studied. Preoperative serum CA-125 levels were compared between various pelvic conditions using F statistics. Multiple regression was employed to determine significant correlates of elevated serum CA-125, and the receiver operating characteristic curve was applied to assess the utility of serum CA-125 in preoperative preparation. Based on the two-sample Student t test, the sample size required to detect a difference in mean serum CA-125 levels of one-half of one standard deviation with a power of 90% when the sample size ratio of the two groups was 1:50 was 675 with a significance level of 5%.
RESULTS: The mean serum CA-125 levels (IU/mL) for American Society of Reproductive Medicine stages I, II, III, and IV endometriosis were 18.8 +/- 0.9, 40.3 +/- 2.8, 77.1 +/- 3.5, and 182.4 +/- 14.0, respectively. CA-125 levels were significantly increased with advanced stages (P <.001, F test). Furthermore, serum CA-125 levels were significantly higher in patients with more extensive adhesions to the peritoneum, omentum, ovary, fallopian tube, colon, and cul-de-sac, or with ruptured endometrioma (P <.001, F test). We then classified patients with at least one of the three factors including dense omentum adhesion, ruptured endometrioma, and complete cul-de-sac obliteration as the high-risk group that required preoperative bowel preparation, and the others as the low-risk group. Receiver operating characteristic curve analyses set a cutoff point of 65 IU/mL, which gave a sensitivity of 76%, a specificity of 71%, a positive predictive value of 76%, and a negative predictive value of 93.2%.
CONCLUSION: Our results suggest that preoperative CA-125 assay is useful to decide which women should receive preoperative bowel preparation. Endometriosis patients with preoperative CA-125 levels higher than 65 IU/mL are at high risk for severe pelvic adhesions that warrant thorough preoperative bowel preparation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11864662     DOI: 10.1016/s0029-7844(01)01731-8

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  18 in total

1.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

2.  Chronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer.

Authors:  Babatunde O Akinwunmi; Ana Babic; Allison F Vitonis; Daniel W Cramer; Linda Titus; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-09-20       Impact factor: 4.254

3.  Rhizoctonia bataticola lectin induces apoptosis and inhibits metastasis in ovarian cancer cells by interacting with CA 125 antigen differentially expressed on ovarian cells.

Authors:  Prajna Hegde; Sindhura B R; Suhas Ballal; Bale M Swamy; Shashikala R Inamdar
Journal:  Glycoconj J       Date:  2021-11-08       Impact factor: 2.916

4.  Comparison of HE4 and CA125 levels in women with benign gynecologic disorders : Does age or menopausal status matter?

Authors:  Ratko Delić; Mario Štefanović; Štefka Krivec; Vladimir Weber; Jakob Koren
Journal:  Wien Klin Wochenschr       Date:  2016-10-17       Impact factor: 1.704

5.  Clinical and histological profile of surgically managed benign adnexal masses.

Authors:  Vaidyanathan Gowri; Maryam Al Shukri; Maha Al Khaduri; Lovina Machado
Journal:  Oman Med J       Date:  2014-05

Review 6.  Blood biomarkers for the non-invasive diagnosis of endometriosis.

Authors:  Vicki Nisenblat; Patrick M M Bossuyt; Rabia Shaikh; Cindy Farquhar; Vanessa Jordan; Carola S Scheffers; Ben Willem J Mol; Neil Johnson; M Louise Hull
Journal:  Cochrane Database Syst Rev       Date:  2016-05-01

7.  Endometrial CXCL13 expression is cycle regulated in humans and aberrantly expressed in humans and Rhesus macaques with endometriosis.

Authors:  Jason M Franasiak; Katherine A Burns; Ov Slayden; Lingwen Yuan; Marc A Fritz; Kenneth S Korach; Bruce A Lessey; Steven L Young
Journal:  Reprod Sci       Date:  2014-07-16       Impact factor: 3.060

8.  Imaging in gynaecology: How good are we in identifying endometriomas?

Authors:  C Van Holsbeke; B Van Calster; S Guerriero; L Savelli; F Leone; D Fischerova; A Czekierdowski; R Fruscio; J Veldman; G Van de Putte; A C Testa; T Bourne; L Valentin; D Timmerman
Journal:  Facts Views Vis Obgyn       Date:  2009

9.  Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.

Authors:  Noriaki Arakawa; Hiroshi Kobayashi; Naohiro Yonemoto; Yusuke Masuishi; Yoko Ino; Hiroshi Shigetomi; Naoto Furukawa; Norihisa Ohtake; Yohei Miyagi; Fumiki Hirahara; Hisashi Hirano; Etsuko Miyagi
Journal:  PLoS One       Date:  2016-10-31       Impact factor: 3.240

10.  Correlation of CA-125 serum level and clinico-pathological characteristic of patients with endometriosis.

Authors:  Mojgan Karimi-Zarchi; Najmeh Dehshiri-Zadeh; Leili Sekhavat; Fahime Nosouhi
Journal:  Int J Reprod Biomed (Yazd)       Date:  2016-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.